Drug data last refreshed 42m ago · AI intelligence enriched 2w ago
CARDIZEM CD is an extended-release oral capsule formulation of diltiazem hydrochloride, a non-dihydropyridine calcium channel blocker used to treat hypertension and angina. The drug works by inhibiting calcium influx into vascular smooth muscle and cardiac conduction tissue, resulting in vasodilation and reduced heart rate. It has been a cornerstone therapy in cardiovascular disease management since its approval in 1991.
Declining commercial footprint signals smaller field teams, reduced headcount growth, and shift toward maintenance vs. expansion roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CARDIZEM CD offers limited career growth in a LOE-stage product; roles focus on defending market share against generics, managing declining sales, and optimizing payer relationships. Professionals on this team should expect smaller headcount, lower visibility, and eventual transition opportunities as the brand enters post-LOE phase.
Worked on CARDIZEM CD at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo